

Tigecycline-induced Hypofibrinogenaemia in a Patient with End-stage Renal Disease

S Wang, Z Li, L Li, F Liu

ABSTRACT

Tigecycline is a broad-spectrum antibiotic agent used to treat severe or multidrug-resistant (MDR) bacterial infections. Bacterial infection is a common and severe complication or comorbidity associated with end-stage renal disease (ESRD). However, few cases have been reported regarding the adverse drug reactions of tigecycline in patients with ESRD. Here, we detail the case of a 19-year-old female with ESRD, who received tigecycline to treat her sepsis due to an MDR Staphylococcus aureus. Following 7 days of tigecycline, the patient developed coagulopathy with hypofibrinogenaemia, although there was no subsequent haemorrhage. The hypofibrinogenaemia resolved within 14 days after the discontinuation of tigecycline. Therefore, we recommend that clinicians strictly monitor the coagulation parameters in patients with ESRD during tigecycline treatment.

Keywords: End-stage renal disease, hypofibrinogenaemia, tigecycline.

INTRODUCTION

Tigecycline presents excellent reactions against a broad spectrum of bacteria including multidrug-resistant Gram-negative bacteria (1). Bacterial infection is a common and severe complication of end-stage renal disease (ESRD), for which the choice of antibiotics is difficult due to drug metabolism and renal insufficiency. Tigecycline represents an effective alternative, but concerns remain regarding the safety of tigecycline in patients with ESRD. Here, we report a case of an ESRD patient infected by *Staphylococcus aureus* who experienced hypofibrinogenaemia with the use of tigecycline.

CASE REPORT

A 19-year-old Tibetan girl presented with recurrent facial oedema and fatigue. She was diagnosed with chronic renal disease in Tibetan clinics and treated with traditional Tibetan medicine for 1 year. Two months before her admission, her oedema exacerbated, with cough, expectoration, dyspnoea, coma, recurrent high fever, dyskinesia in the right upper limb and epilepsy. The laboratory tests indicated that she was suffering from hypertension, severe anaemia, significant increase of serum creatinine (685 $\mu\text{mol/L}$) and white blood cell (WBC) count ($19.3 \times 10^9/\text{L}$), pulmonary infections, a left

cerebral infarction and encephalatrophy. She had been administered antibiotics (amoxicillin-sulbactam, imipenem and moxifloxacin), regular haemodialysis, invasive mechanical ventilation and other supportive treatments, but her symptoms did not disappear.

On her admission, the patient was conscious and her vital signs were acceptable. The laboratory tests revealed the following: WBC $15.48 \times 10^9/\text{L}$, haemoglobin 84 g/L, serum creatinine 286.0 $\mu\text{mol/L}$ and albumin 25.3 g/L. Her sputum culture showed Gram-positive streptococcus. Blood from her peripheral vein and venous catheter in addition to urine were collected and sent for Gram stain microbiological culture.

This patient urgently needed a powerful antibiotic agent and broad-spectrum antibiotic coverage. Because the patient had prior exposure to many antibiotics, tigecycline was selected as the antibiotic medicine. Tigecycline monotherapy (50 mg q12 h iv) was initiated, and its efficacy was later confirmed by the isolation of tigecycline-sensitive *Staphylococcus aureus* from her blood culture and a sensitive *Escherichia coli* from her urine culture. New catheters were inserted, and regular haemodialysis and other supportive treatments were administered.

From: Division of Nephrology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.

Correspondence: Dr F Liu, Division of Nephrology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Email: liufangfh@163.com; wss_0815@163.com

After the start of tigecycline therapy, symptoms of fever, cough and expectoration gradually disappeared, and no spasm occurred. The patient's WBC count (Fig. 1) and other inflammatory parameters (*eg*, PCT and CRP) were strictly monitored and improved dramatically. However, we observed hypofibrinogenaemia (1.73 g/L), and worsening of prothrombin time (PT) and activated partial thromboplastin time (APTT) on day 7 of the tigecycline treatment (Fig. 2). As no signs of haemorrhage or disseminated intravascular coagulation (DIC) were observed, we did not change the treatment strategy. On day 11, her fibrinogen decreased sharply

to an intolerable 0.86 g/L, with a slight declination in PT and fluctuation of APTT (Fig. 2B). At this point, tigecycline was discontinued, as it was suspected to be responsible for this coagulation disorder. Moxifloxacin and vancomycin were selected as antibiotics after tigecycline withdrawal according to the drug sensitivity tests. Meanwhile, we administered fresh-frozen plasma transfusions to protect the patient from bleeding.

From that day onward, her fibrinogen climbed slowly and steadily to reach the lower limit of normal, and PT and APTT stayed within the normal range. Fourteen days after the discontinuation of tigecycline, her fibrinogen improved and remained within the normal level without the administration of fresh-frozen plasma transfusions (Fig. 2A). Repeated blood, urine and sputum cultures found no evidence of bacterial growth. The patient recovered and remained stable without any recurrence of fever, cough, epilepsy or coagulation disorder. The patient is now waiting for a kidney transplant.

DISCUSSION

Tigecycline is a relatively novel antibiotic agent with powerful antibiotic reactions against a wide spectrum of bacterial organisms. Tigecycline is mainly metabolised by the liver, and it requires no dosage adjustment in patients with renal impairment (2), making it a good alternative for infections in patients with chronic renal disease or ESRD. In our case, an ESRD patient presented with sepsis, severe and complicated bacterial infection, and high risk of persisting infections, as




Fig. 1: Trend in WBC level. A gradual decrease in WBC counts with tigecycline administration (black bar) and other antibiotics following withdrawal of tigecycline (white bar). WBC = white blood cell.




Fig. 2: Trends in fibrinogen level and PT/APTT with (black bar) or without (white bar) use of tigecycline. (A) A remarkable decrease in fibrinogen on day 7–11 of tigecycline administration, resolved gradually by its withdrawal. (B) Fluctuation of PT and APTT with the use of tigecycline and improved by its withdrawal. PT = prothrombin time; APTT = activated partial thromboplastin time.

well as resistance to numerous antibiotics. Tigecycline resolved her symptoms and improved her parameters of infections. Hypofibrinogenaemia occurred after 7 days of tigecycline treatment and was relieved after tigecycline was discontinued, with no changes in other therapies. Sepsis or severe infection was the most likely cause of her hypofibrinogenaemia; however, systemic inflammation and the general condition of the patient were improving at onset. Other causes of hypofibrinogenaemia included congenital hypofibrinogenaemia, DIC, leukaemia, malignant tumour, severe liver diseases and hemophagocytic syndrome; nevertheless, the patient displayed no evidence of these diseases. Thus, we hypothesised that hypofibrinogenaemia was a side effect of tigecycline.

It is suggested that tigecycline causes nausea, vomiting, pancreatitis, hepatic injury or failure and hypoglycaemia with a relatively high frequency (3). However, few cases of hypofibrinogenaemia have been reported as an adverse drug reaction to tigecycline. Rossitto presented a case of tigecycline-induced coagulopathy and hypofibrinogenaemia in a patient with advanced liver cirrhosis (4). Pieringer reported a case in which the use of tigecycline was associated with hypofibrinogenaemia in an ESRD patient undergoing continuous ambulatory peritoneal dialysis (5). In addition to this case, this study further indicates that tigecycline is a probable cause of hypofibrinogenaemia in patients with ESRD.

Hypofibrinogenaemia is rarely found in ESRD patients. In contrast, these patients have increased levels of fibrinogen, which directly contributes to a hypercoagulable state (6, 7), thus increasing the risk of venous thromboembolism (8, 9). However, coagulation disorders, which increase the risk of bleeding, are the common complications in ESRD patients; the most prominent abnormality is the prolongation of skin bleeding time (10), while APTT or PT is usually in the normal range. In this study, the fibrinogen level in the patient was initially normal, but it dropped with the use of tigecycline and recovered after the discontinuation of this drug. Therefore, we believe that tigecycline caused hypofibrinogenaemia in this ESRD patient.

Due to the increasing use of tigecycline for treating complicated infections, more attention should be paid to the adverse drug reactions associated with this drug. In conclusion, we strongly recommend the strict monitoring of fibrinogen and other coagulation parameters in patients who are receiving tigecycline as an antibiotic agent.

ACKNOWLEDGEMENTS

Many thanks to the patient, her family, and all the medical and paramedical staff of West China Hospital of Sichuan University.

REFERENCES

1. Frampton JE, Curran MP. Tigecycline (vol 65, p. 2631, 2005). *Drugs* 2006; **66**: 448.
2. Korth-Bradley JM, Troy SM, Matschke K, Muralidharan G, Fruncillo RJ, Speth JL et al. Tigecycline pharmacokinetics in subjects with various degrees of renal function. *J Clin Pharmacol* 2012; **52**: 1379–87.
3. Kadoyama K, Sakaeda T, Tamon A, Okuno Y. Adverse event profile of tigecycline: data mining of the public version of the US Food and Drug Administration adverse event reporting system. *Biol Pharm Bull* 2012; **35**: 967–70.
4. Rossitto G, Piano S, Rosi S, Simioni P, Angeli P. Life-threatening coagulopathy and hypofibrinogenaemia induced by tigecycline in a patient with advanced liver cirrhosis. *Eur J Gastroen Hepat* 2014; **26**: 681–4.
5. Pieringer H, Schmekal B, Biesenbach G, Pohanka E. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline. *Ann Hematol* 2010; **89**: 1063–4.
6. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. *Circulation* 2003; **107**: 87–92.
7. de la Serna G. Fibrinogen: a new major risk factor for cardiovascular disease. A review of the literature. *J Fam Pract* 1994; **39**: 468–77.
8. Parikh AM, Spencer FA, Lessard D, Emery C, Baylin A, Linkletter C et al. Venous thromboembolism in patients with reduced estimated GFR: a population-based perspective. *Am J Kidney Dis* 2011; **58**: 746–55.
9. Pavord S, Myers B. Bleeding and thrombotic complications of kidney disease. *Blood Rev* 2011; **25**: 271–8.
10. Boccardo P, Remuzzi R, Galbusera M. Platelet dysfunction in renal failure. *Semin Thromb Hemost* 2004; **30**: 579–89.

© West Indian Medical Journal 2026.

This is an article published in open access under a Creative Commons Attribution International licence (CC BY). For more information, please visit https://creativecommons.org/licenses/by/4.0/deed.en_US.

